SG11201407787VA - A method of improving liver function - Google Patents

A method of improving liver function

Info

Publication number
SG11201407787VA
SG11201407787VA SG11201407787VA SG11201407787VA SG11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA
Authority
SG
Singapore
Prior art keywords
international
victoria
geelong
street
liver function
Prior art date
Application number
SG11201407787VA
Other languages
English (en)
Inventor
Ken Walder
Guy Krippner
Geoff Nicholson
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of SG11201407787VA publication Critical patent/SG11201407787VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11201407787VA 2012-05-24 2013-03-15 A method of improving liver function SG11201407787VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US201261666574P 2012-06-29 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Publications (1)

Publication Number Publication Date
SG11201407787VA true SG11201407787VA (en) 2014-12-30

Family

ID=49622927

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407787VA SG11201407787VA (en) 2012-05-24 2013-03-15 A method of improving liver function
SG10201705388XA SG10201705388XA (en) 2012-05-24 2013-03-15 A Method Of Improving Liver Function

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201705388XA SG10201705388XA (en) 2012-05-24 2013-03-15 A Method Of Improving Liver Function

Country Status (15)

Country Link
US (2) US20150150855A1 (cg-RX-API-DMAC7.html)
EP (1) EP2854807A4 (cg-RX-API-DMAC7.html)
JP (2) JP6360826B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150023405A (cg-RX-API-DMAC7.html)
CN (2) CN104487073A (cg-RX-API-DMAC7.html)
BR (1) BR112014029308A2 (cg-RX-API-DMAC7.html)
CA (1) CA2874513A1 (cg-RX-API-DMAC7.html)
CO (1) CO7160082A2 (cg-RX-API-DMAC7.html)
HK (1) HK1209051A1 (cg-RX-API-DMAC7.html)
MX (1) MX362111B (cg-RX-API-DMAC7.html)
NZ (2) NZ702645A (cg-RX-API-DMAC7.html)
RU (1) RU2653478C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201407787VA (cg-RX-API-DMAC7.html)
WO (1) WO2013173859A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408704B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
ES2660170T3 (es) * 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction

Also Published As

Publication number Publication date
EP2854807A4 (en) 2016-03-16
MX362111B (es) 2019-01-07
CN109498623A (zh) 2019-03-22
JP6412241B2 (ja) 2018-10-24
WO2013173859A1 (en) 2013-11-28
KR20150023405A (ko) 2015-03-05
RU2653478C2 (ru) 2018-05-08
ZA201408704B (en) 2018-07-25
HK1209051A1 (en) 2016-03-24
SG10201705388XA (en) 2017-07-28
CO7160082A2 (es) 2015-01-15
MX2014014317A (es) 2015-08-10
US20150150855A1 (en) 2015-06-04
CA2874513A1 (en) 2013-11-28
RU2014152196A (ru) 2016-07-20
EP2854807A1 (en) 2015-04-08
JP2015517534A (ja) 2015-06-22
US20180333399A1 (en) 2018-11-22
JP6360826B2 (ja) 2018-07-18
NZ723206A (en) 2018-02-23
CN104487073A (zh) 2015-04-01
BR112014029308A2 (pt) 2017-06-27
NZ702645A (en) 2016-08-26
JP2018090589A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
SG11201407200TA (en) Liquid formulation
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201808990QA (en) Compositions for topical application of compounds
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201407427WA (en) Extreme pcr
SG11201909009TA (en) Catheter securement device with window
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201407747QA (en) A method and apparatus for facilitating the management of health and security
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201408185UA (en) Improved frame for climbing screen
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201407800SA (en) Selective binding of biological targets to solid phase ureides
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201408163VA (en) Modified fibronectin fragments or variants and uses thereof
SG11201408119PA (en) Systems and methods for data center cooling and water desalination
SG11201909003YA (en) Integrated vascular access device and anchor pad
SG11201407801VA (en) Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
SG11201407924RA (en) METHOD OF TREATING <i>SCEDOSPORIUM SPP</i>. INFECTION